More supply for AtCor
Wednesday, 08 October, 2008
AtCor Medical [ASX: ACG] has signed an agreement to supply its SphygmoCor systems and clinical trial support services to an international pharmaceutical company.
The contract is worth at least US$930,000 [AUD$1.3 million], and has brought to US$3.7 million [AUD$5.2 million] the total value of pharmaceutical trial contracts secured by AtCor in the past 130 days.
SphygmoCor visibly identifies the effects of reflected blood pressure in the central aortic wave. This measure can't be detected with standard blood pressure monitoring.
mRNA successfully delivered through blood–brain barrier
Getting mRNA into the brain could allow scientists to instruct brain cells to produce therapeutic...
Biological computer could revolutionise medical sciences
The CL1 is a commercial biological computer which fuses lab-cultivated neurons from human stem...
Genetic risk of schizophrenia impacts men and women differently
Men tend to present different clinical symptoms from women, poorer premorbid functioning and...
